What is HER2?

European Journal of Oncology Nursing

Volumn 4, Issue SUPPL.1, 2000, Pages 2-9

  Cooke, Tim ^a  

^a GLASGOW ROYAL INFIRMARY   (United Kingdom)

Author keywords

Breast cancer; c erbB 2; Human epidermal growth factor receptor 2; Oncogene; Oncogenesis

Indexed keywords

EID: 0002857064     PISSN: 14623889     EISSN: None     Source Type: Journal    
DOI: 10.1054/ejon.2000.0072     Document Type: Article

References (55)

1. Aaronson SA (1991) Growth factors and cancer. Science 254: 1146-1153
2. Agnantis NJ, Parissi P, Anagnostakis D, Spandidos DA (1986) Comparative study of Harvey-ras oncogene expression with conventional clinicopathologic parameters of breast cancer. Oncology 43: 36-39.
3. Akiyama T, Sudo C, Ogawara H, Toyoshima K, Yamamoto T (1986) The product of the human c-erbB-2 gene: A 185-kilodalton glycoprotein with tyrosine kinase activity. Science 232: 1644-1646
4. Akiyama T, Saito T, Ogawara H, Toyoshima K, Yamamoto T (1988) Tumor promoter and epidermal growth factor stimulate phosphorylation of the c-erbB-2 gene product in MKN-7 human adenocarcinoma cells. Molecular Cellular Biology 8: 1019-1026
5. Alroy I, Yarden Y (1997) The ErbB signaling network in embryogenesis and oncogenesis: signal diversification through ligand-receptor combinatorial interactions. FEBS Letters 410: 83-86
6. Barnes DM, Bartkova J, Camplejohn RS Gullick WJ, Smith PJ, Millis RR (1992) Overexpression of the c-erbB-2 oncogene: why does this occur more frequently in ductal carcinoma in situ than in invasive mammary carcinoma and is this of prognostic significance. European Journal of Cancer 28: 644-648
7. Benz CC, Scott GK, Sarup JC, Johnson RM, Tripathy D, Coronado E, Shepard HM, Osborne CK (1992) Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. Breast Cancer Research and Treatment 24: 85-95
8. Berns EM, Klijn JG, van Staveren IL, Portengen H, Noordegraaf E, Foekens JA (1992) Prevalence of amplification of the oncogenes c-myc, HER2/neu, and int-2 in one thousand human breast tumours: correlation with steroid receptors. European Journal of Cancer 28: 697-700
9. Chazin VR, Kaleko M, Miller AD, Slamon DJ (1992) Transformation mediated by the human HER-2 gene independent of epidermal growth factor receptor. Oncogene 7: 1859-1866
10. Chong D, Cooke TG, Reeves JR, George WD, Mallon EA, Ozanne B (1999a) Quantitation of EGFR and c-erbB-2 expression in preinvasive compared to invasive breast cancer. European Journal of Cancer 35 (Suppl 4): S201 [abstract 792A]
11. Chong D, Cooke TG, Reeves JR, George WD, Mallon EA, Ozanne B, Stanton P (1999b) Quantitation of c-erbB-2 in primary breast cancer allows identification of a further poor prognostic group. European Journal of Cancer 35 (Suppl 4): S89 [abstract 291]
12. Connelly PA, Stern DF (1990) The epidermal growth factor receptor and the product of the neu protooncogene are members of a receptor tyrosine phosphorylation cascade. Proceedings of the National Academy of Sciences USA 87: 6054-6057
13. Cossman J, Schlegel R (1991) p53 in the diagnosis of human neoplasia. Journal of the National Cancer Institute 83 980-981
14. Coussens L, Yang-Feng TL, Liao Y-C, Chen E, Gray A, McGrath J, Seeburg PH, Libermann TA, Schlessinger J, Francke U, Levinson A, Ullrich A (1985) Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 230: 1132-1139
15. DiAusgustine R, Richards RG (1997) EGF-related peptides and their receptors in mammary gland development. Journal of Mammary Gland Biology and Neoplasia 2: 109-118
16. Di Fiore PP, Pierce JH, Fleming TP, Hazan R, Ullrich A, King CR, Schlessinger J, Aaronson SA (1987a) Overexpression of the human EGF receptor confers an EGF-dependent transformed phenotype to NIH 3T3 cells. Cell 51: 1063-1070
17. Di Fiore PP, Pierce JH, Kraus MH, Segatto O, King CR, Aaronson SA (1987b) erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells. Science 237: 178-182
18. Escot C, Theillet C, Liderau R (1986) Genetic alteration of the c-myc protooncogene (MYC) in human primary breast carcinomas. Proceedings of the National Academy of Sciences USA 83: 4834-4848
19. Graus-Porta D, Beerli RR, Daly JM, Hynes NE (1997) ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signalling. EMBO Journal 16: 1647-1655
20. Halter SA, Dempsey P, Matsui Y, Stokes MK, Graves-Deal R, Hogan BL, Coffey RJ (1992) Distinctive patterns of hyperplasia in transgenic mice with mouse mammary tumor virus transforming growth factor-alpha. Characterization of mammary gland and skin proliferations. American Journal of Pathology 140: 1131-1146
21. Harris JR, Lippman ME, Veronesi U, Willett W (1992) Breast cancer. New England Journal of Medicine 327: 473-480
22. Hortobagyi GN, Hung M-C, Buzdar AU (1999) Recent developments in breast cancer therapy. Seminars in Oncology 26 (Suppl 12): 11-20
23. HER2 causes transformation and tumorigenesis of NIH 3T3 cells. Proceedings of the National Academy of Sciences USA 84: 7159-7163
24. Hynes NE, Stern DF (1994) The biology of erbB-2/neu/ HER-2 and its role in cancer. Biochimica et Biophysica Acta 1198: 165-184
25. Kim YC, Park KO, Kern JA, Park CS, Lim SC, Jang AS, Yang JB (1998) The interactive effect of ras, HER2, p53 and bcl-2 expression in predicting the survival of non-small cell lung cancer patients. Lung Cancer 22: 181-190
26. Kokai Y, Meyers JN, Wada T, Brown VI, LeVea CM, Davis JG, Dobashi K, Greene MI (1989) Synergistic interaction of p185c-neu and the EGF receptor leads to transformation of rodent fibroblasts. Cell 58: 287-292
27. Kovach JS, McGovern RM, Cassady JD, Swanson SK, Wold LE, Vogelstein B, Sommer SS (1991) Direct sequencing from touch preparations of human carcinomas: analysis of p53 mutations in breast carcinoma. Journal of the National Cancer Institute 83: 1004-1009
28. Lei S, Appert HE, Nakata B, Domenico DR, Kim K, Howard JM (1995) Overexpression of HER2/neu oncogene in pancreatic cancer correlates with shortened survival. International Journal of Pancreatology 17: 15-21
29. Lemmon MA, Schlessinger J (1994) Regulation of signal transduction and signal diversity by receptor oligomerization. Trends in Biochemical Science 19: 459-463
30. Lewis GD, McMurtrey AE, Bauer KD, Sliwkowski MX (1993) Proceedings of the American Association of Cancer Research 34: 523
31. Lidereau R, Callahan R, Dickson E, Peters G, Escot G, Ali I (1988) Amplification of the int-2 gene in primary human breast tumours. Oncogene Research 2: 285-291
32. Liu E, Thor A, He M, Barcos M, Ljung B-M, Benz C (1992) The HER2 (c-erbB-2) oncogene is frequently amplified in in situ carcinomas of the breast. Oncogene 7: 1027-1032
33. McKenzie SJ, Marks PJ, Lam T, Morgan J, Panicali DL, Trimpe KL, Carney WP (1989) Generation and characterization of monoclonal antibodies specific for the human neu oncogene product, p185. Oncogene 4: 543-548
34. Marchionni MA, Goodearl AD, Chen MS, Bermingham-McDonogh O, Kirk C, Hendricks M, Danehy F, Misumi D, Sudhalter J, Kobayashi K, Wroblewski D, Lynch C, Baldassare M, Hiles I, Davis JB, Hsuan JJ, Totty NF, Otsu M, McBurney RN, Waterfield MD, Stroobant P, Gwynne D (1993) Glial growth factors are alternatively spliced erbB2 ligands expressed in the nervous system. Nature 362: 312-318
35. Mark E (1999) HER2 status: implications for patients. Eur J Oncol Nursing 4 (Suppl 1)
36. Marte BM, Jeschke M, Graus-Porta D, Taverna D, Hofer P, Groner B, Yarden Y, Hynes NE (1995) Neu differentiation factor/heregulin modulates growth and differentiation of HC11 mammary epithelial cells. Molecular Endocrinology 9: 14-23
37. Normanno N, Ciardiello F (1997) EGF-related peptides in the pathophysiology of the mammary gland. Journal of Mammary Gland Biology and Neoplasia 2: 143-152
38. Orr-Urtreger A, Trakhtenbrot L, Ben-Levy R, Wen D, Rechavi G, Lonai P, Yarden Y (1993) Neural expression and chromosomal mapping of Neu differentiation factor to 8 pp12-21. Proceedings of the National Academy of Sciences USA 90: 1867-1871
39. Pauletti G, Godolphin W, Press MF, Slamon DJ (1996) Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization. Oncogene 13: 63-72
40. Peles E, Bacus SS, Koski RA, Lu HS, Wen D, Ogden SG, Ben Levy R, Yarden Y (1992) Isolation of the neu/ HER-2 stimulatory ligand: a 44 kd glycoprotein that induces differentiation of mammary tumor cells. Cell 69: 205-216
41. Pinkas-Kramarski R, Eilam R, Alroy I, Levkowitz G, Lonai P, Yarden Y (1997) Differential expression of NDF/neuregulin receptors ErbB-3 and ErbB-4 and involvement in inhibition of neuronal differentiation. Oncogene 15: 2803-2815
42. Plowman G, Green J, Culouscou J-M, Carlton G, Rothwell V, Buckley S (1993) Heregulin induces tyrosine phosphorylation of HER4/p180erbB4. Nature 366: 473-475
43. Press MF, Cordon-Cardo C, Slamon DJ (1990) Expression of the HER2/neu proto-oncogene in normal adult and fetal tissues. Oncogene 5: 953-962
44. Riviere A, Becker J, Loning T (1991) Comparative investigation of c-erbB2/neu expression in head and neck tumors and mammary cancer. Cancer 67: 2142-2149
45. Sarup JC, Johnson RM, King KL, Fendly BM, Lipari MT, Napier MA, Ullrich A, Shepard HM (1991) Characterization of an anti-p185HER2 monoclonal antibody that stimulates receptor functions and inhibits tumor cell growth. Growth Regulation 1: 72-82
46. Schroeder W, Lee DC (1998) Dynamic expression and activation of ErbB receptors in the developing mouse mammary gland. Cell Growth and Differentiation 9: 451-464
47. Schroeder W, Biesterfeld S, Zillessen R, Rath W (1997) Epidermal growth factor receptor-immunohistochemical detection and clinical significance for treatment of primary breast cancer. Anticancer Research 17: 2799-2802
48. Shi D, He G, Cao S, Pan W, Zhang H-X, Yu D, Hung M-C (1992) Overexpression of the c-erbR-2/neu-encoded p185 protein in primary lung cancer. Molecular Carcinogenesis 5: 213-218
49. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL (1987). Human breast cancer: correlation of relapse and survival with amplification of the Her-2/neu oncogene. Science 235: 177-182
50. Slamon D, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A, Press MF (1989). Studies of the HER-2/neu protooncogene in human breast and ovarian cancer. Science 244: 707-712
51. Sliwkowski MX, Schaefer G, Akita RW, Lofgren JA, Fitzpatrick VD, Nuijens A, Fendly BM, Cerione RA, Vandlen RL, Carraway KL III (1994) Coexpression of erbB2 and erbB3 proteins reconstitutes a high affinity receptor for heregulin. Journal of Biological Chemistry 269: 14661-14665
52. van der Geer P, Hunter T, Lindberg RA (1994) Receptor protein-tyrosine kinases and their signal transduction pathways. Annual Reviews in Cell Biology 10: 251-337
53. Vennstrom B, Bishop JM (1982) Isolation and characterization of chicken DNA homologous to the two putative oncogenes of avian erythroblastosis virus. Cell 28: 135-143
54. Venter DJ, Tizi NL, Kumar S, Gullick WJ (1987) Overexpression of the c-erbB-2 oncoprotein in human breast carcinomas: immunohistological assessment correlates with gene amplification. Lancet 2: 69-72
55. Weiner DB, Nordberg J, Robinson R, Nowell PC, Gazdar A, Greene MI, Williams WV, Cohen JA, Kern JA (1990) Expression of the neu gene-encoded protein (P185neu) in human non-small cell carcinomas of the lung. Cancer Research 50: 421-425